China’s new policies on foreign investment in healthcare and biotech

Free trade zones in Beijing, Shanghai, Guangdong, and Hainan are designed to attract capital into China’s fast-growing healthcare sectors, says Li Mi of Lusheng.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Asia

IndiaMart v CDSCO: A test of intermediary liability

31 March 2026 The clash between one of India’s largest B2B marketplaces and the country’s drugs regulator challenges the “passive” position of such platforms with regards to allegedly unlawful pharmaceutical listings, says Aarti Aggarwal of Remfry & Sagar.

Asia

Part I: Ozempic goes generic as Novo’s key patent expires

20 March 2026 As the patent protecting semaglutide—the drug that made Novo Nordisk one of Europe's most valuable companies—expires in ten countries, the pressure mounts for prices and market leaders alike.

Asia

AstraZeneca partners with Chinese firm ahead of next obesity race

5 February 2026 The British-Swedish pharma giant pays $1.2 billion upfront for access to next-generation weight-loss treatment as China patent cliff changes the market.

More features

UPC refuses early knockout in Illumina–Element dispute

IndiaMart v CDSCO: A test of intermediary liability

CRISPR priority feud ends at USPTO as board reaches decision

Novartis bets $2bn on biologics as Xolair patents fade

mRNA litigation: Who’s winning, who’s filing, and what’s next

EPO reports record patent filings, but pharma and biotech lag

Part I: Ozempic goes generic as Novo’s key patent expires

J&J unit targets former employee over alleged mass data theft

China’s new policies on foreign investment in healthcare and biotech

More on this story

Editor's picks

Editor's picks

More features